VADs Set To Enter Big Leagues With St. Jude's Plan To Acquire Thoratec
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical says it will pay $3.4 billion to own ventricular-assist device leader Thoratec, pointing to significant synergies in the heart failure and interventional cardiology markets. The deal would thrust VADs into a diversified cardiology firm for the first time, and it includes a "go-shop" period that leaves an opening for other big device firms to enter competing bids.